Aegis Capital Starts Immunic Inc. (IMUX) at Buy

April 15, 2021 9:59 AM EDT
Get Alerts IMUX Hot Sheet
Price: $12.50 -4.58%

Rating Summary:
    10 Buy, 0 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 30 | Down: 4 | New: 24
Trade Now! 
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

Aegis Capital analyst Nathan Weinstein initiates coverage on Immunic Inc. (NASDAQ: IMUX) with a Buy rating and a price target of $55.00.

The analyst commented, "We are initiating coverage on shares of Immunic with a BUY rating and a $55 price target. Our price target is based on a discounted cash flow valuation. Key inputs to the valuation include credit for IMU-838 in RRMS and UC, with a 58% and 33% PoS, respectively, along with a 20% discount rate. Additional assets and indications are treated as option value at this time. At Dec 31st, Immunic reported $127mm of cash and equivalents. Risks include: 1) clinical, 2) financial, 3) regulatory, 4) competition, 5) reimbursement, and 6) other."

For an analyst ratings summary and ratings history on Immunic Inc. click here. For more ratings news on Immunic Inc. click here.

Shares of Immunic Inc. closed at $14.52 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, New Coverage